This company has been marked as potentially delisted and may not be actively trading. Anchiano Therapeutics (ANCN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ANCN vs. XLO, FBLG, STTK, SPRO, CELU, SCYX, HOWL, ELYM, RMTI, and LTRNShould you be buying Anchiano Therapeutics stock or one of its competitors? The main competitors of Anchiano Therapeutics include Xilio Therapeutics (XLO), FibroBiologics (FBLG), Shattuck Labs (STTK), Spero Therapeutics (SPRO), Celularity (CELU), SCYNEXIS (SCYX), Werewolf Therapeutics (HOWL), Eliem Therapeutics (ELYM), Rockwell Medical (RMTI), and Lantern Pharma (LTRN). These companies are all part of the "medical" sector. Anchiano Therapeutics vs. Xilio Therapeutics FibroBiologics Shattuck Labs Spero Therapeutics Celularity SCYNEXIS Werewolf Therapeutics Eliem Therapeutics Rockwell Medical Lantern Pharma Anchiano Therapeutics (NASDAQ:ANCN) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends. Do institutionals & insiders hold more shares of ANCN or XLO? 9.1% of Anchiano Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 6.9% of Anchiano Therapeutics shares are owned by insiders. Comparatively, 5.2% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is ANCN or XLO more profitable? Anchiano Therapeutics' return on equity of 36.08% beat Xilio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Anchiano TherapeuticsN/A 36.08% 27.40% Xilio Therapeutics N/A -211.50%-80.31% Which has better earnings and valuation, ANCN or XLO? Anchiano Therapeutics has higher earnings, but lower revenue than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnchiano TherapeuticsN/AN/A-$27.12M-$3.46-0.40Xilio Therapeutics$6.34M6.12-$76.40M-$1.28-0.59 Which has more volatility & risk, ANCN or XLO? Anchiano Therapeutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500. Do analysts prefer ANCN or XLO? Xilio Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 433.19%. Given Xilio Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Xilio Therapeutics is more favorable than Anchiano Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anchiano Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor ANCN or XLO? In the previous week, Xilio Therapeutics had 1 more articles in the media than Anchiano Therapeutics. MarketBeat recorded 1 mentions for Xilio Therapeutics and 0 mentions for Anchiano Therapeutics. Xilio Therapeutics' average media sentiment score of 1.87 beat Anchiano Therapeutics' score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Anchiano Therapeutics Neutral Xilio Therapeutics Very Positive Does the MarketBeat Community favor ANCN or XLO? Anchiano Therapeutics received 46 more outperform votes than Xilio Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Xilio Therapeutics an outperform vote while only 65.91% of users gave Anchiano Therapeutics an outperform vote. CompanyUnderperformOutperformAnchiano TherapeuticsOutperform Votes5865.91% Underperform Votes3034.09% Xilio TherapeuticsOutperform Votes1275.00% Underperform Votes425.00% SummaryXilio Therapeutics beats Anchiano Therapeutics on 9 of the 16 factors compared between the two stocks. Get Anchiano Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANCN vs. The Competition Export to ExcelMetricAnchiano TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.17M$6.84B$5.55B$8.04BDividend YieldN/A2.95%5.09%4.22%P/E Ratio9.137.4422.6818.83Price / SalesN/A257.63404.28106.72Price / CashN/A65.8538.1834.62Price / Book0.686.576.794.33Net Income-$27.12M$143.14M$3.22B$247.97M Anchiano Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANCNAnchiano TherapeuticsN/A$1.37+1.5%N/A+86.1%$10.17MN/A9.1316XLOXilio Therapeutics3.5364 of 5 stars$0.76-3.2%$4.00+426.3%-30.1%$39.35M$6.34M-0.4470News CoverageGap DownFBLGFibroBiologics2.8527 of 5 stars$1.04-8.8%$13.00+1,156.0%-87.1%$39.06MN/A-3.0410Short Interest ↓Positive NewsSTTKShattuck Labs2.5367 of 5 stars$0.81+0.6%$7.50+827.1%-90.1%$38.85M$5.72M-0.53100Earnings ReportNews CoveragePositive NewsGap DownSPROSpero Therapeutics4.3553 of 5 stars$0.69-2.8%$5.00+624.6%-57.3%$38.57M$27.40M9.86150Short Interest ↑CELUCelularity0.3253 of 5 stars$1.61+2.9%N/A-48.0%$38.33M$48.20M0.00220SCYXSCYNEXIS1.1681 of 5 stars$0.98+1.1%N/A-42.9%$38.32M$3.75M-1.3360Upcoming EarningsAnalyst ForecastPositive NewsGap UpHOWLWerewolf Therapeutics2.2836 of 5 stars$0.85+1.1%$9.00+953.9%-85.5%$38.28M$1.89M-0.5640News CoverageELYMEliem TherapeuticsN/A$1.27-2.3%N/A-82.3%$37.79MN/A-2.409Gap DownRMTIRockwell Medical4.3829 of 5 stars$1.10-3.1%$4.00+265.3%-29.9%$37.42M$101.49M-21.90300Short Interest ↓Positive NewsGap UpLTRNLantern Pharma2.5174 of 5 stars$3.46+0.3%$25.00+622.5%-32.8%$37.32MN/A-1.9420Upcoming EarningsNews Coverage Related Companies and Tools Related Companies XLO Alternatives FBLG Alternatives STTK Alternatives SPRO Alternatives CELU Alternatives SCYX Alternatives HOWL Alternatives ELYM Alternatives RMTI Alternatives LTRN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANCN) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anchiano Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anchiano Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
